AstraZeneca plc (LON:AZN) had its price target raised by investment analysts at HSBC Holdings plc from GBX 4,150 ($54.76) to GBX 4,340 ($57.27) in a research note issued to investors on Wednesday. The firm currently has a “reduce” rating on the biopharmaceutical company’s stock. HSBC Holdings plc’s target price would suggest a potential downside of 13.75% from the stock’s current price.

Other research analysts also recently issued reports about the stock. Kepler Capital Markets restated a “buy” rating and issued a GBX 5,500 ($72.58) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Liberum Capital restated a “buy” rating and issued a GBX 5,500 ($72.58) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Citigroup Inc. restated a “buy” rating and issued a GBX 6,000 ($79.18) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,700 ($75.22) target price on shares of AstraZeneca plc in a research note on Friday, July 28th. Finally, Berenberg Bank set a GBX 5,500 ($72.58) target price on shares of AstraZeneca plc and gave the company a “buy” rating in a research note on Friday, July 28th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the stock. AstraZeneca plc currently has an average rating of “Hold” and an average price target of GBX 5,183.55 ($68.40).

Shares of AstraZeneca plc (AZN) traded up 2.44% during midday trading on Wednesday, hitting GBX 5155.00. 3,643,526 shares of the stock were exchanged. The firm has a 50 day moving average of GBX 5,011.54 and a 200 day moving average of GBX 4,931.21. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The firm’s market cap is GBX 65.26 billion.

TRADEMARK VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://theolympiareport.com/2017/11/01/hsbc-holdings-plc-reiterates-gbx-4340-price-target-for-astrazeneca-plc-azn.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.